Biofil Chemicals & Pharmaceuticals growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue−15.0%−1.9%
EBITDA−23.4%−17.8%
Net Income+400.0%+70.6%
EPS (adj.)+400.0%+70.6%
Total Assets−15.9%+10.9%
Total Equity+14.8%+7.6%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

BIOFILCHEM₹29.26

Biofil Chemicals & Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersMANGALAMVINEETLABLASAORTINGLOBEKREBSBIOALPABALPHARMANATCAPSUQMcap ₹47.6 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue-15.0-1.9
EBITDA-23.4-17.8
Net Income+400.0+70.6
EPS (adj.)+400.0+70.6
Total Assets-15.9+10.9
Total Equity+14.8+7.6
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.